Keywords: astrazeneca, shares, dip, despite, rise, eps, ceo
AstraZeneca's shares dip despite 41% rise in EPS, as CEO's guidance disappoints
Article | 07 August 2006
The UK's second largest drugmaker, Astra Zeneca, posted a 10% increase in second-quarter 2006 sales at constant exchange rates (plus 8% in actual ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
